# Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

> **NCT04047472** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 397 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Brolucizumab 6mg
- **DRUG:** Aflibercept 2 mg

## Key facts

- **NCT ID:** NCT04047472
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-29
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047472, "Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04047472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*